Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
127.67
-0.73 (-0.57%)
At close: Nov 12, 2024, 4:00 PM
129.01
+1.34 (1.05%)
Pre-market: Nov 13, 2024, 5:30 AM EST
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 195.92, with a low estimate of 140 and a high estimate of 289. The average target predicts an increase of 53.46% from the current stock price of 127.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ASND stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Buy | 4 | 4 | 4 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +33.16% | Nov 4, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $180 → $174 | Buy | Maintains | $180 → $174 | +36.29% | Oct 23, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $157 → $160 | Strong Buy | Maintains | $157 → $160 | +25.32% | Oct 21, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $175 → $191 | Strong Buy | Maintains | $175 → $191 | +49.60% | Sep 23, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $264 → $289 | Buy | Maintains | $264 → $289 | +126.36% | Sep 17, 2024 |
Financial Forecast
Revenue This Year
294.18M
from 266.72M
Increased by 10.30%
Revenue Next Year
558.99M
from 294.18M
Increased by 90.02%
EPS This Year
-7.62
from -8.55
EPS Next Year
-3.87
from -7.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 335.8M | 786.5M | 1.7B | ||
| Avg | 294.2M | 559.0M | 1.1B | ||
| Low | 259.1M | 400.1M | 810.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 25.9% | 167.3% | 211.1% | ||
| Avg | 10.3% | 90.0% | 88.0% | ||
| Low | -2.9% | 36.0% | 44.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -6.39 | -0.35 | 14.26 | ||
| Avg | -7.62 | -3.87 | 3.50 | ||
| Low | -8.60 | -6.75 | -2.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.